Qube Research & Technologies (QRT)’s Vertex Pharmaceuticals VRTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33M	Sell	4,700 -3,500	-43%	-$1.55M	﹤0.01%	2057
2026 Q1	$3.66M	Sell	8,200 -16,900	-67%	-$7.88M	﹤0.01%	1823
2025 Q4	$11.4M	Buy	25,100 +6,600	+36%	+$2.84M	0.01%	1263
2025 Q3	$7.25M	Buy	18,500 +7,000	+61%	+$2.93M	0.01%	1517
2025 Q2	$5.12M	Buy	11,500 +9,400	+448%	+$4.33M	0.01%	1681
2025 Q1	$1.02M	Sell	2,100 -22,700	-92%	-$10.6M	﹤0.01%	2250
2024 Q4	$9.99M	Sell	24,800 -25,300	-50%	-$11.7M	0.01%	1089
2024 Q3	$23.3M	Buy	50,100 +49,800	+16,600%	+$23.9M	0.03%	604
2024 Q2	$141K	Buy	+300	New	+$130K	﹤0.01%	2526
2023 Q4	–	Sell	-9,600	Closed	-$3.34M	–	4777
2023 Q3	$3.34M	Buy	+9,600	New	+$3.36M	0.01%	1129

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VRTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 3,998 shares — an estimated $1.77M sold.

Qube Research & Technologies (QRT) first reported a position in VRTX in Q1 2018 and held it in 22 quarters. The position peaked at $233M in Q1 2024. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 3,998 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.77M.
Qube Research & Technologies (QRT) first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 22 quarters.
Qube Research & Technologies (QRT)'s Vertex Pharmaceuticals position peaked at $233M in Q1 2024.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.